Why the study?
Does pioglitazone improve lipoprotein metabolism in patients with type 2 diabetes mellitus?
Does pioglitazone improve lipoprotein metabolism in patients with type 2 diabetes mellitus?
Pioglitazone lowers VLDL triglycerides in patients with type 2 diabetes by enhancing lipoprotein lipase-mediated lipolysis and reducing apoC-III production.
Answers are grounded in this paper and cite their sources.
May aid triglyceride management in T2DM; extends mechanistic understanding of thiazolidinedione effects on lipoprotein kinetics.
Elevated plasma levels of VLDL triglycerides (TGs) are characteristic of patients with type 2 diabetes mellitus (T2DM) and are associated with increased production rates (PRs) of VLDL TGs and apoB. Lipoprotein lipase–mediated (LPL-mediated) lipolysis of VLDL TGs may also be reduced in T2DM if the level of LPL is decreased and/or the level of plasma apoC-III, an inhibitor of LPL-mediated lipolysis, is increased. We studied the effects of pioglitazone (Pio), a PPARγ agonist that improves insulin sensitivity, on lipoprotein metabolism in patients with T2DM. Pio treatment reduced TG levels by increasing the fractional clearance rate (FCR) of VLDL TGs from the circulation, without changing direct removal of VLDL particles. This indicated increased lipolysis of VLDL TGs during Pio treatment, a mechanism supported by our finding of increased plasma LPL mass and decreased levels of plasma apoC-III. Lower apoC-III levels were due to reduced apoC-III PRs. We saw no effects of Pio on the PR of either VLDL TG or VLDL apoB. Thus, Pio, a PPARγ agonist, reduced VLDL TG levels by increasing LPL mass and inhibiting apoC-III PR. These 2 changes were associated with an increased FCR of VLDL TGs, almost certainly due to increased LPL-mediated lipolysis.
No takes yet. Share an insight, caveat, or question.
Nagashima et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: